Struggling to find Insulin Aspart (NovoLog) in 2026? Learn why this essential diabetes medication is hard to find and what you can do about it.
You go to your pharmacy to pick up your Insulin Aspart prescription, and the pharmacist tells you it's out of stock. You try another pharmacy — same story. If this has happened to you, you're not imagining things. Insulin Aspart, sold under brand names like NovoLog and Fiasp, has been increasingly difficult to find at pharmacies across the United States in 2026.
For the millions of Americans who rely on this rapid-acting insulin to manage type 1 and type 2 diabetes, running low isn't just an inconvenience — it can be a medical emergency. In this article, we'll explain exactly why Insulin Aspart is hard to find right now, and more importantly, what you can do about it.
Insulin Aspart is a rapid-acting insulin analog used to control blood sugar spikes around mealtimes. It starts working within about 15 minutes of injection, peaks in 1 to 3 hours, and lasts for 3 to 5 hours. It's manufactured by Novo Nordisk and sold under several brand names:
Insulin Aspart is prescribed for both adults and children with type 1 diabetes, and for adults with type 2 diabetes who need mealtime insulin coverage. It's typically used alongside a long-acting (basal) insulin like Insulin Degludec (Tresiba) or Insulin Glargine (Lantus). To learn more about the medication itself, check out our guide on what Insulin Aspart is and how it's used.
There's no single reason behind the Insulin Aspart shortage — it's a combination of factors that have created a perfect storm for patients.
Novo Nordisk, the sole manufacturer of NovoLog and Fiasp, has experienced ongoing manufacturing delays since 2024. These delays have affected multiple formulations, particularly Fiasp FlexTouch pens and Fiasp vials. The American Society of Health-System Pharmacists (ASHP) has been tracking these shortages, and some products have been on the shortage list for over a year.
In late 2025, Novo Nordisk discontinued its unbranded biologic Insulin Aspart — the more affordable authorized generic that many patients depended on. This product was originally introduced to help patients save money, but its removal from the market has reduced overall supply and pushed more patients toward brand-name NovoLog and Fiasp, increasing demand for those products.
Like many medications, insulin products are affected by broader pharmaceutical supply chain challenges. Insulin is a biologic product that requires specialized manufacturing facilities, cold-chain storage, and careful distribution. Any disruption along this chain — from raw materials to pharmacy shelves — can create shortages that take months to resolve.
The number of Americans living with diabetes continues to grow. The CDC estimates that over 38 million Americans have diabetes, and more than 8 million use insulin. As demand rises and supply tightens, pharmacies in some areas are hit harder than others.
For the latest information on the current supply situation, read our Insulin Aspart shortage update for 2026.
Running out of Insulin Aspart is not something you should have to deal with, but there are practical steps you can take right now.
Instead of calling pharmacy after pharmacy, use Medfinder to search for pharmacies near you that have Insulin Aspart in stock. Medfinder checks real-time availability so you can find what you need without wasting time.
Large chain pharmacies often run out of high-demand medications first because they serve more patients. Independent pharmacies may have stock that chains don't. They also tend to have more flexibility in ordering from different distributors. Check our tips on how to find Insulin Aspart in stock near you.
If Insulin Aspart is truly unavailable in your area, your doctor may be able to switch you to another rapid-acting insulin such as Insulin Lispro (Humalog) or Insulin Glulisine (Apidra). These medications work similarly and may be more readily available. Learn about your options in our article on alternatives to Insulin Aspart.
Novo Nordisk's NovoCare program can help you find supply or connect you with patient assistance. Call 1-888-668-6444 or visit novocare.com for help locating your medication.
This is the most important advice: never skip your insulin doses without talking to your doctor first. For people with type 1 diabetes, missing insulin can lead to diabetic ketoacidosis (DKA), which is a life-threatening emergency. If you're running low and can't find your medication, call your doctor or go to an urgent care or emergency room immediately.
While Novo Nordisk has stated it is working to resolve manufacturing issues, there is no definitive end date for the shortage as of early 2026. The discontinuation of the unbranded generic has complicated the picture further. However, the introduction of biosimilar Insulin Aspart products like Kirsty and Trurapi in some markets could eventually help improve supply.
In the meantime, patients should stay proactive — use tools like Medfinder to track availability, keep an open line of communication with their prescriber, and explore savings programs to reduce costs if they need to switch formulations.
The Insulin Aspart shortage is a real and frustrating problem, but you do have options. By understanding why the shortage is happening and taking proactive steps to find your medication, you can stay on top of your diabetes management. Don't hesitate to reach out to your healthcare provider, use availability tools, and explore alternative medications if needed.
Your health comes first — and there are people and tools ready to help you find what you need.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
